Salinomycin, monosodium salt; salinomycin monosodium salt hydrate; Salinomycin-Natrium; natrium salinomycin; Salinomycin (sodium salt); salinomycin sodium; SALINOMYCIN SODIUM SALT 2.5-HYDRATE; Salinomycin hydrate monosodium salt; Salinomycin 1-sodium salt
物化属性
LogP
4.78900
PSA
173.27000
储存条件
保持贮藏器密封、储存在阴凉、干燥的地方,确保工作间有良好的通风或排气装置
外观
白色或淡黄色结晶粉末,带有特殊的气味
比旋光度
D25 -37° (c = 1 in ethanol)
溶解度
安全信息
安全说明
危险品运输编号:2811
WGK Germany:3
危险等级:6.1
包装类别:III
生产及用途
用途与制备
生物活性
Salinomycin sodium salt (Salinomycin sodium),一种钾离子载体抗生素,是 Wnt/β-catenin 信号传导的有效抑制剂。Salinomycin sodium salt (Salinomycin sodium) 作用于 Wnt/Fzd/LRP 复合物,阻断 Wnt 诱导的 LRP6 磷酸化,导致 LRP6 蛋白降解。Salinomycin sodium salt (Salinomycin sodium) 选择性抑制人肿瘤干细胞。
靶点
Wnt/β-catenin
体外研究
Salinomycin (0.1-8 µM) inhibits the growth of HUVECs in a dose-dependent manner, accounting for 32.1 and 59.2% inhibition at 4 and 8 µM, respectively. HUVECs exposed to 2, 4 and 8 µM of Salinomycin for 48 h show a dose-dependent reduction in cell number and a change in cell morphology. Salinomycin (4 µM) treatment effectively inhibits HUVEC migration and invasion, and significantly disrupt the capillary-like tube formation of HUVECs. Salinomycin significantly suppresses the expression levels of phosphorylated (p)-FAK in a time- and dose-dependent manner in HUVECs. Salinomycin inhibits HUVEC angiogenesis by disturbing the VEGF-VEGFR2-AKT signaling axis. Combination of RSVL and Salinomycin synergistically inhibits the proliferation of TNBC (MDA-MB-231) cells. RSVL and Salinomycin effectively reduce wound healing, colony and tumorosphere forming capability in TNBC cells. Synergistic combination of RSVL and Salinomycin induces apoptosis in both culture conditions by significant upregulation of Bax with decreased Bcl-2 expression as comparison to untreated and alone drug treatments. Salinomycin (0, 2, 4, 8 and 16 μM) significantly inhibits the proliferation of A2780 and SK-OV-3 cell lines in a dose- and time-dependent manner, (IC
50 24h
: 13.8 μM, IC
50 48h
: 6.888 μM and IC
50 72h
: 4.382 μM for A2780 cell lines), (IC
50 24h
: 12.7 μM, IC
50 48h
: 9.869 μM and IC
50 72h
: 5.022 μM for SK-OV-3 cell lines). Salinomycin blocks the Wnt/β-catenin pathway in EOC cells. Salinomycin (2 μM) reduces cancer cell proliferation, inhibits STAT3 phosphorylation and P38 and β-catenin expressions, and suppresses epithelial-mesenchymal transition in colorectal cancer cells. Salinomycin (1-5 μM) inhibits cancer cell proliferation and STAT3 signaling in colorectal cancer cells. Furthermore, Salinomycin activates Akt (Ser 473) and down-regulates Hsp27 (Ser 82) phosphorylation in HT-29 and SW480. Salinomycin down-regulates hTERT and reduces telomerase activity when combined with telomerase inhibitor.
溶于二甲基亚砜
熔点
140-142 ºC
稳定性
如果遵照规格使用和储存则不会分解,未有已知危险反应
精确质量
790.48400
体内研究
Salinomycin (5 and 10 mg/kg) significantly supresses the average tumor volume and tumor weight. Salinomycin hinders the U251 human glioma cell growth in vivo via inhibition of angiogenesis with involvement of AKT and FAK dephosphorylation. Salinomycin (0.5 mg/kg b.wt.) enhances the mean survival time of the tumor bearing Swiss albino mice.